Taihsin Pharmaceutical Announces Board Approval of Consolidated Financial Report for Q2 2026

1. Date reported to or approved by the board of directors: 115/08/11 2. Date approved by the Audit Committee: 115/08/11 3. Reporting period for financial statements or self-compiled annual financial information: Start date ~ End date (YYY/MM/DD ~ YYY/MM/DD): 115/01/01 ~ 115/06/30 4. Cumulative operating revenue from January 1 to the end of this period (in thousands of NT$): 48,448 5. Cumulative gross profit (loss) from January 1 to the end of this period (in thousands of NT$): 34,849 6. Cumulative operating income (loss) from January 1 to the end of this period (in thousands of NT$): (86,340) 7. Cumulative pre-tax net profit (loss) from January 1 to the end of this period (in thousands of NT$): (80,372) 8. Cumulative net profit (loss) for the period from January 1 to the end of this period (in thousands of NT$): (82,874) 9. Cumulative net profit (loss) attributable to owners of the parent from January 1 to the end of this period (in thousands of NT$): (82,896) 10. Cumulative basic earnings (loss) per share from January 1 to the end of this period (in NT$): (0.55) 11. Total assets at the end of the period (in thousands of NT$): 1,925,904 12. Total liabilities at the end of the period (in thousands of NT$): 554,094 13. Equity attributable to owners of the parent at the end of the period (in thousands of NT$): 1,371,255 14. Other matters to be disclosed: None